Jefferies & Company Initiates Coverage For Celera Corporation (CRA) With Buy Rating

Analysts Bruce Cranna and Kelley Roche at Jefferies & Company have initiated coverage of Celera Corporation (NASDAQ: CRA) with a Buy rating. The price target for the company has been set at $9.50.

According to analysts, the company has redefined itself as a developer of innovative clinical lab tests and services, with particular strength in genetic testing for cardiovascular disease. Analysts at Jefferies & Company believe that Celera Corporation offers significant upside potential, considering the ongoing build up of an assay portfolio to check for genetic risk for cardiovascular treatment and predict treatment response.

Learn how to find the best stocks to trade each day in our 70 page E-Book and 90 minute online video for free.